S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:PTPI

Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis

$0.67
-0.03 (-4.29%)
(As of 04/19/2024 ET)
Today's Range
$0.67
$0.70
50-Day Range
$0.68
$1.72
52-Week Range
$0.64
$9.54
Volume
161,716 shs
Average Volume
623,190 shs
Market Capitalization
$4.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Petros Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
496.9% Upside
$4.00 Price Target
Short Interest
Healthy
3.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Petros Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.09 out of 5 stars

PTPI stock logo

About Petros Pharmaceuticals Stock (NASDAQ:PTPI)

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

PTPI Stock Price History

PTPI Stock News Headlines

Petros Pharmaceuticals (NASDAQ:PTPI) Trading Down 2.1%
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Petros Pharmaceuticals Inc Ordinary Shares PTPI
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Petros Pharmaceuticals Inc (PTPI)
Petros Pharma Stock (NASDAQ:PTPI) Insider Trades
Petros Pharmaceuticals initiated with bullish view at Maxim
Petros Pharmaceuticals Inc Ordinary Shares
See More Headlines
Receive PTPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/01/2024
Today
4/21/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PTPI
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+496.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-8,160,000.00
Net Margins
-181.87%
Pretax Margin
-140.21%

Debt

Sales & Book Value

Annual Sales
$5.82 million
Book Value
$4.04 per share

Miscellaneous

Free Float
4,375,000
Market Cap
$4.61 million
Optionable
Not Optionable
Beta
1.91
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives


PTPI Stock Analysis - Frequently Asked Questions

Should I buy or sell Petros Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Petros Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTPI shares.
View PTPI analyst ratings
or view top-rated stocks.

What is Petros Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued 12-month price objectives for Petros Pharmaceuticals' stock. Their PTPI share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 496.9% from the stock's current price.
View analysts price targets for PTPI
or view top-rated stocks among Wall Street analysts.

How have PTPI shares performed in 2024?

Petros Pharmaceuticals' stock was trading at $1.41 at the start of the year. Since then, PTPI stock has decreased by 52.5% and is now trading at $0.6701.
View the best growth stocks for 2024 here
.

Are investors shorting Petros Pharmaceuticals?

Petros Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 146,200 shares, an increase of 65.4% from the March 15th total of 88,400 shares. Based on an average daily trading volume, of 1,080,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 3.6% of the shares of the company are short sold.
View Petros Pharmaceuticals' Short Interest
.

When is Petros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our PTPI earnings forecast
.

How were Petros Pharmaceuticals' earnings last quarter?

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) posted its earnings results on Monday, April, 1st. The company reported ($2.17) earnings per share for the quarter. The firm had revenue of ($0.36) million for the quarter. Petros Pharmaceuticals had a negative net margin of 181.87% and a negative trailing twelve-month return on equity of 68.90%.

When did Petros Pharmaceuticals' stock split?

Shares of Petros Pharmaceuticals reverse split on Wednesday, November 30th 2022. The 1-10 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Petros Pharmaceuticals?

Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PTPI) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners